0000950170-23-027702.txt : 20230613 0000950170-23-027702.hdr.sgml : 20230613 20230613163052 ACCESSION NUMBER: 0000950170-23-027702 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230609 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230613 DATE AS OF CHANGE: 20230613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 231011608 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-20230609.htm 8-K 8-K
0001478320false00014783202023-06-092023-06-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2023 (June 09, 2023)

 

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1165 Eastlake Avenue East

 

Seattle, Washington

 

98109

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 9, 2023, Adaptive Biotechnologies Corporation (the "Company") Board of Directors (the "Board") member Leslie Trigg submitted her resignation from the Board. The resignation was voluntary and not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2023, the Company held its annual meeting of shareholders (the "Annual Meeting") pursuant to notice duly given. Three proposals were presented for voting: Proposal 1: election of two Class 1 directors to the Board (Drs. Katey Owen and Robert Hershberg); Proposal 2: an advisory request concerning compensation for the Company's 2022 named executive officers; and, Proposal 3: ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2023. A quorum of the shareholders voted by the conclusion of the Annual Meeting. The final results of the voting are set forth below.

 

Proposal 1: Election of Class 1 Directors

 

Dr. Katey Owen

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

83,072,262

76.66 %

13,147,625

Against

-

-

Withhold/Abstain

25,282,278

23.33 %

Dr. Robert Hershberg

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

47,703,083

44.02 %

13,147,625

Against

-

-

Withhold/Abstain

60,651,457

55.97 %

 

Proposal 2: Advisory Vote Concerning the 2022 Compensation of the Company's Named Executive Officers

 

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

89,592,587

82.68 %

13,147,625

Against

17,467,529

16.12 %

Withhold/Abstain

1,294,424

1.19 %

 

Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2023

 

Votes Submitted

As % of Proposal Votes

Broker Non Vote

For

121,162,529

99.72 %

0

Against

200,965

0.16 %

Withhold/Abstain

138,671

0.11 %

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date:

June 13, 2023

By:

/s/ Tycho Peterson

 

 

 

Tycho Peterson
Chief Financial Officer

 

 EX-101.SCH 2 adpt-20230609.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 adpt-20230609_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 adpt-20230609_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Jun. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 09, 2023
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Emerging Growth Company false
Securities Act File Number 001-38957
Entity Incorporation, State or Country Code WA
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code (206)
Local Phone Number 659-0067
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
XML 6 adpt-20230609_htm.xml IDEA: XBRL DOCUMENT 0001478320 2023-06-09 2023-06-09 0001478320 false 8-K 2023-06-09 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 (206) 659-0067 Not Applicable false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -F#S58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #9@\U6?[YT6>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R(E'!R;UI:.G#@8K;.QF;+4UBQ-C:R1]^R5>FS*V!]C1TN]/ MGT"-"=+T$9]C'S"2PW0W^K9+TH0U.Q$%"9#,";U.Y93HIN:ACU[3](Q'"-I\ MZ"-"S?D*/)*VFC3,P"(L1*8::Z2)J*F/%[PU"SY\QC;#K %LT6-'":JR J;F MB>$\M@W< #.,,/KT74"[$'/U3VSN +LDQ^26U# ,Y2!R;MJA@K>GW4M>MW!= M(MT9G'XE)^D<<,VNDU_%YG&_9:KFM2CXJJC$ON92<'G_\#Z[_O"["?O>NH/[ MQ\970=7 K[M07U!+ P04 " #9@\U6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M -F#S5;__)$PG@0 ' 1 8 >&PO=V]R:W-H965T&UL MC9AM<^(V$,>_BH9V.GP%/+$M5Y(A^?9= M&;!I:M:\ ;K38WZL-^PC>P /U',IP%Z=73,SE940+V8P\0#FK=&O-AS=-0/XO]%SA.* /T1*BR3[8_/-MR:LQ+ ME1;1T1@)HB ^?//7HR/.#)J7#)RC@9-Q'UZ443YRS8=]*?9,FJ=1S5QD4\VL M$2Z(S:HLM,1? [33PT?AI>ADS=S89^-8!_J-3>+#:J/7^G6-+S&/UKVCX,-! MT+D@^%L:WS&K=\,N' Y5L"97"T>??V*P'1 MS"&:I(J+!'Y&\2GDFS(*VG[-0P4$1ROG:%WGC#G(0)B \AF&9:E?:*4LC+(X MJ@JD=L[6)A6/P?T,F\"$$D).>51*1NNXC^Y\.?D^9@^3V7(\^C*=/8A[TH=7]A7>RH!I)[2Y4!K3WY]!]S(*+?#!L=H?*92B M.-AT3G\2'GIEOA4QE>8J1-JMWBTV[V2:*^J"?55A..L=;YCIF[%Y>X(-PF)X M'6HO2/ OUMZ*MTP%=JI)$F)V6M&;H2@<-IWM?V#9T!";$A:E\3'MJ5(V6JBJ ME#E%R7#HI+X0.$$L9EA?O^'.E $/2]M>6J62IZ@.#IW*YQ)N/70/8&HX]+K8 M;N+"SM;K\L"KT*LD.SL;EC")=OQ$ O6S]:=Z?!8@O-56RY)[J)$.'0Z M7TKNF_A;O$4K41Y]%4>2Q_F2(BDJ@D/G[Y/+V/C5V_)X Q=S1X70U%T\NK^7 M,=7/SL_FOXAOW#2WBH6P1B7KKH/"\G"\/PRT2+(C]4IH/*!GEUO@&''F ?Q] M+80^#&PO M9KEMWDOSAR+DCO9*ZW="C<\W[)&D/ M1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O M:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\" MO @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9 MY=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL) MBS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W M3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y M]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5T MR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00, MX[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/ M+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^ M>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( -F#S5:7BKL

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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports adpt-20230609.htm adpt-20230609.xsd adpt-20230609_lab.xml adpt-20230609_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-20230609.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "adpt-20230609.htm" ] }, "labelLink": { "local": [ "adpt-20230609_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20230609_pre.xml" ] }, "schema": { "local": [ "adpt-20230609.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20230609", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "adpt-20230609.htm", "contextRef": "C_55917acf-7b24-4e0a-a0b7-ad57578e3623", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "adpt-20230609.htm", "contextRef": "C_55917acf-7b24-4e0a-a0b7-ad57578e3623", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptivebiotech.com/20230609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-027702-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-027702-xbrl.zip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end